These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 29584670)
1. Computational Simulation Studies on the Binding Selectivity of 1-(1H-Benzimidazol-5-yl)-5-aminopyrazoles in Complexes with FGFR1 and FGFR4. Pan YL; Liu YL; Chen JZ Molecules; 2018 Mar; 23(4):. PubMed ID: 29584670 [TBL] [Abstract][Full Text] [Related]
2. Theoretical studies on FGFR isoform selectivity of FGFR1/FGFR4 inhibitors by molecular dynamics simulations and free energy calculations. Fu W; Chen L; Wang Z; Kang Y; Wu C; Xia Q; Liu Z; Zhou J; Liang G; Cai Y Phys Chem Chem Phys; 2017 Feb; 19(5):3649-3659. PubMed ID: 28094372 [TBL] [Abstract][Full Text] [Related]
3. Structural insights into FGFR kinase isoform selectivity: diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4. Tucker JA; Klein T; Breed J; Breeze AL; Overman R; Phillips C; Norman RA Structure; 2014 Dec; 22(12):1764-1774. PubMed ID: 25465127 [TBL] [Abstract][Full Text] [Related]
4. Insight into resistance mechanisms of AZD4547 and E3810 to FGFR1 gatekeeper mutation via theoretical study. Liang D; Chen Q; Guo Y; Zhang T; Guo W Drug Des Devel Ther; 2017; 11():451-461. PubMed ID: 28255231 [TBL] [Abstract][Full Text] [Related]
5. FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy. Quintanal-Villalonga Á; Ferrer I; Guruceaga E; Cirauqui C; Marrugal Á; Ojeda L; García S; Zugazagoitia J; Muñoz-Galván S; Lopez-Rios F; Montuenga L; Vicent S; Molina-Pinelo S; Carnero A; Paz-Ares L EBioMedicine; 2020 Mar; 53():102683. PubMed ID: 32114392 [TBL] [Abstract][Full Text] [Related]
6. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. Tan L; Wang J; Tanizaki J; Huang Z; Aref AR; Rusan M; Zhu SJ; Zhang Y; Ercan D; Liao RG; Capelletti M; Zhou W; Hur W; Kim N; Sim T; Gaudet S; Barbie DA; Yeh JR; Yun CH; Hammerman PS; Mohammadi M; Jänne PA; Gray NS Proc Natl Acad Sci U S A; 2014 Nov; 111(45):E4869-77. PubMed ID: 25349422 [TBL] [Abstract][Full Text] [Related]
7. Developing FGFR4 inhibitors as potential anti-cancer agents via in silico design, supported by in vitro and cell-based testing. Ho HK; Németh G; Ng YR; Pang E; Szántai-Kis C; Zsákai L; Breza N; Greff Z; Horváth Z; Pató J; Szabadkai I; Szokol B; Baska F; Őrfî L; Ullrich A; Kéri G; Chua BT Curr Med Chem; 2013; 20(10):1203-17. PubMed ID: 23409720 [TBL] [Abstract][Full Text] [Related]
8. Molecular simulation studies on the binding selectivity of 2-anilino-4-(thiazol-5-yl)-pyrimidines in complexes with CDK2 and CDK7. Chohan TA; Qian HY; Pan YL; Chen JZ Mol Biosyst; 2016 Jan; 12(1):145-61. PubMed ID: 26565382 [TBL] [Abstract][Full Text] [Related]
9. Crystal Structure of the FGFR4/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455. Wu D; Guo M; Philips MA; Qu L; Jiang L; Li J; Chen X; Chen Z; Chen L; Chen Y PLoS One; 2016; 11(9):e0162491. PubMed ID: 27618313 [TBL] [Abstract][Full Text] [Related]
10. Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity. Alsamarah A; LaCuran AE; Oelschlaeger P; Hao J; Luo Y PLoS One; 2015; 10(7):e0132221. PubMed ID: 26133550 [TBL] [Abstract][Full Text] [Related]
11. 3D-QSAR, docking and molecular dynamics simulations of novel Pyrazolo-pyridazinone derivatives as covalent inhibitors of FGFR1: a scientific approach for possible anticancer agents. Hamza S; Abid A; Khanum A; Chohan TA; Saleem H; Maqbool Khan K; Khurshid U; Butt J; Anwar S; Alafnan A; Ansari SA; Qayyum A; Raza A; Chohan TA J Biomol Struct Dyn; 2024 Mar; 42(5):2242-2256. PubMed ID: 37211823 [TBL] [Abstract][Full Text] [Related]
12. Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects. Lu X; Chen H; Patterson AV; Smaill JB; Ding K J Med Chem; 2019 Mar; 62(6):2905-2915. PubMed ID: 30403487 [TBL] [Abstract][Full Text] [Related]
13. Probing Dual Covalent Irreversible Inhibition of EGFR/FGFR4 by Electrophilic-Based Natural Compounds to Overcome Resistance and Enhance Combination Therapeutic Potentials and Management of Hepatocellular Carcinoma (HCC). Xue H; Chen P; Jiao J; Zhu X Protein J; 2024 Aug; 43(4):793-804. PubMed ID: 38981944 [TBL] [Abstract][Full Text] [Related]
14. 2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors. Li X; Guise CP; Taghipouran R; Yosaatmadja Y; Ashoorzadeh A; Paik WK; Squire CJ; Jiang S; Luo J; Xu Y; Tu ZC; Lu X; Ren X; Patterson AV; Smaill JB; Ding K Eur J Med Chem; 2017 Jul; 135():531-543. PubMed ID: 28521156 [TBL] [Abstract][Full Text] [Related]
15. TAS-120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure. Kalyukina M; Yosaatmadja Y; Middleditch MJ; Patterson AV; Smaill JB; Squire CJ ChemMedChem; 2019 Feb; 14(4):494-500. PubMed ID: 30600916 [TBL] [Abstract][Full Text] [Related]
16. FGFR4 and its novel splice form in myogenic cells: Interplay of glycosylation and tyrosine phosphorylation. Kwiatkowski BA; Kirillova I; Richard RE; Israeli D; Yablonka-Reuveni Z J Cell Physiol; 2008 Jun; 215(3):803-17. PubMed ID: 18186042 [TBL] [Abstract][Full Text] [Related]
17. Structural insights into the interaction of human S100B and basic fibroblast growth factor (FGF2): Effects on FGFR1 receptor signaling. Gupta AA; Chou RH; Li H; Yang LW; Yu C Biochim Biophys Acta; 2013 Dec; 1834(12):2606-19. PubMed ID: 24063890 [TBL] [Abstract][Full Text] [Related]
18. Molecular modeling of pyrrolo-pyrimidine based analogs as potential FGFR1 inhibitors: a scientific approach for therapeutic drugs. Raza A; Chohan TA; Sarfraz M; Chohan TA; Imran Sajid M; Tiwari RK; Ansari SA; Alkahtani HM; Yasmeen Ansari S; Khurshid U; Saleem H J Biomol Struct Dyn; 2023; 41(23):14358-14371. PubMed ID: 36898855 [TBL] [Abstract][Full Text] [Related]
19. Competition for ligands between FGFR1 and FGFR4 regulates Xenopus neural development. Yamagishi M; Okamoto H Int J Dev Biol; 2010; 54(1):93-104. PubMed ID: 20013652 [TBL] [Abstract][Full Text] [Related]
20. Discovery and optimization of triazine derivatives as ROCK1 inhibitors: molecular docking, molecular dynamics simulations and free energy calculations. Shen M; Zhou S; Li Y; Pan P; Zhang L; Hou T Mol Biosyst; 2013 Mar; 9(3):361-74. PubMed ID: 23340525 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]